Filing Details

Accession Number:
0001209191-23-011704
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-22 16:48:42
Reporting Period:
2023-02-17
Accepted Time:
2023-02-22 16:48:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1789815 Ourania Tatsis C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Evp, Chief Reg. & Quality Off. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-02-17 4,498 $292.85 60,947 No 4 F Direct
Common Stock Disposition 2023-02-21 4 $291.01 60,943 No 4 S Direct
Common Stock Disposition 2023-02-21 145 $292.85 60,798 No 4 S Direct
Common Stock Disposition 2023-02-21 207 $293.83 60,591 No 4 S Direct
Common Stock Disposition 2023-02-21 124 $294.77 60,467 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 F Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1.
  2. Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  3. Open market sales reported on this line occurred at a weighted average price of $292.85 (range $292.37 to $293.36).
  4. Open market sales reported on this line occurred at a weighted average price of $293.83 (range $293.39 to $294.38).
  5. Open market sales reported on this line occurred at a weighted average price of $294.77 (range $294.42 to $295.37).